News & Events about Agenus Inc.
Immuno-oncology leader, Agenus (Nasdaq: AGEN), shared promising data today from its Phase 1b trial on the botensilimab and balstilimab combination at a late-breaking session at the 2023 ESMO World...
Agenus (Nasdaq: AGEN), a leading immuno-oncology company dedicated to developing innovative treatments for cancer and infectious diseases, today announced a data update on botensilimab (multifunctional CTLA-4 antibody) in combination with balstilimab (PD-1 antibody) for patients with...
Shares of Agenus Inc. (NASDAQ:AGEN Get Rating) have earned an average rating of Moderate Buy from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average ...
Agenus (Nasdaq: AGEN), a leading immuno-oncology company specializing in immunological agents for cancer and infectious diseases, today announced plans to present clinical data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, to be held June 2-6 in Chicago, IL. Data from a...
Agenus (NASDAQ:AGEN Get Rating)s stock had its buy rating reaffirmed by investment analysts at B. Riley in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $8.00 price target on the biotechnology companys ...